Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 2;24(3):2885.
doi: 10.3390/ijms24032885.

Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics

Tereza Buchtova  1 , David Lukac  1 , Zdenek Skrott  1 , Katarina Chroma  1 , Jiri Bartek  2   3 , Martin Mistrik  1
Affiliations
Review

Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics

Tereza Buchtova et al. Int J Mol Sci. .

Abstract

Cannabidiol (CBD) is an easily accessible and affordable Marijuana (Cannabis sativa L.) plant derivative with an extensive history of medical use spanning thousands of years. Interest in the therapeutic potential of CBD has increased in recent years, including its anti-tumour properties in various cancer models. In addition to the direct anticancer effects of CBD, preclinical research on numerous cannabinoids, including CBD, has highlighted their potential use in: (i) attenuating chemotherapy-induced adverse effects and (ii) enhancing the efficacy of some anticancer drugs. Therefore, CBD is gaining popularity as a supportive therapy during cancer treatment, often in combination with standard-of-care cancer chemotherapeutics. However, CBD is a biologically active substance that modulates various cellular targets, thereby possibly resulting in unpredictable outcomes, especially in combinations with other medications and therapeutic modalities. In this review, we summarize the current knowledge of CBD interactions with selected anticancer chemotherapeutics, discuss the emerging mechanistic basis for the observed biological effects, and highlight both the potential benefits and risks of such combined treatments. Apart from the experimental and preclinical results, we also indicate the planned or ongoing clinical trials aiming to evaluate the impact of CBD combinations in oncology. The results of these and future trials are essential to provide better guidance for oncologists to judge the benefit-versus-risk ratio of these exciting treatment strategies. We hope that our present overview of this rapidly advancing field of biomedicine will inspire more preclinical and clinical studies to further our understanding of the underlying biology and optimize the benefits for cancer patients.

Keywords: cancer; cannabidiol; chemotherapy; drug–drug interaction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Scripture C.D., Figg W.D. Drug Interactions in Cancer Therapy. Nat. Rev. Cancer. 2006;6:546–558. doi: 10.1038/nrc1887. - DOI - PubMed
    1. Pergam S.A., Woodfield M.C., Lee C.M., Cheng G.-S., Baker K.K., Marquis S.R., Fann J.R. Cannabis Use among Patients at a Comprehensive Cancer Center in a State with Legalized Medicinal and Recreational Use. Cancer. 2017;123:4488–4497. doi: 10.1002/cncr.30879. - DOI - PMC - PubMed
    1. Weiss M.C., Hibbs J.E., Buckley M.E., Danese S.R., Leitenberger A., Bollmann-Jenkins M., Meske S.W., Aliano-Ruiz K.E., McHugh T.W., Larson S.L., et al. A Coala-T-Cannabis Survey Study of Breast Cancer Patients’ Use of Cannabis before, during, and after Treatment. Cancer. 2022;128:160–168. doi: 10.1002/cncr.33906. - DOI - PMC - PubMed
    1. Aizpurua-Olaizola O., Soydaner U., Öztürk E., Schibano D., Simsir Y., Navarro P., Etxebarria N., Usobiaga A. Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis Sativa Plants from Different Chemotypes. J. Nat. Prod. 2016;79:324–331. doi: 10.1021/acs.jnatprod.5b00949. - DOI - PubMed
    1. ElSohly M.A., Radwan M.M., Gul W., Chandra S., Galal A. Phytochemistry of Cannabis Sativa L. Prog. Chem. Org. Nat. Prod. 2017;103:1–36. doi: 10.1007/978-3-319-45541-9_1. - DOI - PubMed

LinkOut - more resources